Summary & Overview
HCPCS C9153: Injection, Amisulpride, 1 mg
HCPCS Level II code C9153 designates a 1 mg injection of amisulpride, a medication used in psychiatric care. Nationally, accurate coding for injectable antipsychotics affects billing clarity, inventory tracking, and claims processing across outpatient and facility settings. Clear identification of unit dosing supports appropriate claim adjudication and clinical documentation.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and typical sites of service, plus what to expect in payer considerations. The publication outlines common modifiers associated with procedure reporting, notes where data is unavailable, and highlights benchmarking and policy themes relevant to injectable psychiatric medications.
This resource provides: a definition of the HCPCS Level II code C9153, guidance on where this service is typically rendered, and a summary of payer coverage landscape nationally. Data not available in the input is identified where applicable.
Billing Code Overview
HCPCS Level II code C9153 represents injection, amisulpride, 1 mg. This code is used to report administration of a parenteral dose of amisulpride measured in 1 mg units.
-
Service type: Medication injection
-
Typical site of service: Outpatient clinic, hospital outpatient department, emergency department, or other settings where parenteral antipsychotic or psychiatric medication administration occurs
Clinical & Coding Specifications
Clinical Context
A 34-year-old adult with a diagnosis of treatment-resistant schizophrenia presents to an outpatient behavioral health infusion clinic for pharmacologic management. The provider plans a parenteral administration of amisulpride due to inadequate response or intolerable side effects from oral antipsychotics and to achieve rapid symptom control. The workflow includes pre-administration assessment (vital signs, baseline ECG for QTc assessment, review of concurrent medications), informed consent, preparation of the injectable amisulpride dose by a licensed pharmacist or nurse under protocol, administration via intramuscular or intravenous route per product labeling, observation for acute adverse reactions for at least 30–60 minutes, documentation of the drug lot number and dose, and scheduling follow-up psychiatric evaluation and monitoring for extrapyramidal symptoms and metabolic effects. Billing captures the drug using HCPCS Level II code C9153 for amisulpride per milligram, with the clinic appending appropriate modifiers for unusual circumstances, anesthesia involvement, or partial services as applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when administration required substantially greater resources or time due to complexity (e.g., difficult IV access, severe agitation requiring extended monitoring). |